Medicare GLP-1 Coverage in 2026: The Bridge Program and What Seniors Need to Know

$50 a month for Wegovy or Zepbound: what the Bridge program actually delivers

Medicare has never covered weight loss drugs. That prohibition has been federal law since Part D launched in 2006. On December 23, 2025, CMS found a workaround: a short-term payment demonstration called the Medicare GLP-1 Bridge, running from July 1 through December 31, 2026, that will provide eligible Part D beneficiaries with coverage of specific GLP-1 medications used for weight loss.

The program covers two drugs: Wegovy (both injection and the new tablet form) and Zepbound. Beneficiaries who qualify pay a flat $50 copay per monthly supply, regardless of which Part D benefit phase they're in. Manufacturers Novo Nordisk and Eli Lilly have agreed to provide these medications at a net price of $245 per 30-day supply to the federal government.

Think of the Bridge as a temporary overpass built while the permanent highway is under construction. The permanent highway is the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a CMMI innovation model launching in Medicare Part D in January 2027. The Bridge fills the six-month gap between announcement and full implementation.

Several mechanical details matter for anyone planning to use this program. The Bridge operates entirely outside the normal Part D benefit structure. CMS has designated Humana — already the administrator of the Limited Income Newly Eligible Transition (LI NET) program — as the central processor handling prior authorization, claims adjudication, and pharmacy payments. Pharmacies submit claims to a dedicated BIN/PCN (028918 MEDDGLP1BR), not to the beneficiary's Part D plan.

That separation from Part D has real financial consequences. The $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket maximum. Manufacturer coupons and discount programs cannot be applied to Bridge claims. And for beneficiaries receiving the Low-Income Subsidy (Extra Help), those cost-sharing subsidies do not reduce the $50 copay under the Bridge. That last point matters: KFF has noted that $50 monthly may still be unaffordable for some low-income seniors who would otherwise qualify.

The spending numbers explain the urgency. Gross Medicare Part D spending on GLP-1s hit $27.5 billion in 2024, a five-fold increase from 2019. Two million Part D enrollees took Ozempic alone that year, up from fewer than 150,000 five years earlier. Meanwhile, 56% of GLP-1 users report these drugs are difficult to afford, according to KFF polling. The Bridge addresses both pressures: expanding access while negotiating sharply lower prices.

Three BMI thresholds, different qualifying conditions: who actually qualifies

The Bridge uses a tiered eligibility system based on body mass index combined with specific medical conditions. Your provider must submit a prior authorization request attesting that you meet one of three clinical pathways:

BMI threshold	Additional requirements
≥35	None beyond lifestyle modification commitment
≥30	Diagnosis of heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension (systolic >140 or diastolic >90 despite two medications), or chronic kidney disease stage 3a or above
≥27	Diagnosis of pre-diabetes (per ADA guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease

All pathways require that the beneficiary is at least 18 years old and is being prescribed the drug for weight reduction in combination with ongoing lifestyle modification — structured nutrition and physical activity consistent with the FDA label.

One detail that could save a lot of frustration: CMS assesses BMI at the time you first started GLP-1 therapy, not at the time of your prior authorization request. If you began taking semaglutide in 2024 with a BMI of 37 and have since dropped to 34, your provider should attest that you met the ≥35 threshold when therapy was initiated. This protects people who have already lost weight on these medications from losing their coverage because the drugs are working.

You must be enrolled in a standalone prescription drug plan (PDP) or a Medicare Advantage plan that offers drug coverage (MA-PD) in 2026. Beneficiaries in Special Needs Plans, employer/union group waiver plans, and the LI NET program are eligible. Those in private fee-for-service plans, cost contract plans, PACE organizations, and several other plan types are generally not eligible unless they are also enrolled in a standalone PDP.

Dually-eligible beneficiaries — those enrolled in both Medicare and Medicaid — can participate if they meet the clinical criteria and are in an eligible plan type. This matters because, as we'll see, several states are simultaneously cutting Medicaid GLP-1 coverage for weight loss.

If you're already taking a GLP-1 through Part D for a covered indication like type 2 diabetes or cardiovascular risk reduction, the Bridge does not apply to you. Your medication continues through your Part D plan. The Bridge only covers GLP-1s when used specifically for obesity/weight loss.

From 5% to 100%: the prior authorization wall that changed everything

Before the Bridge program can help anyone, beneficiaries face a barrier that has grown dramatically in recent years. A September 2025 study in JAMA by Dr. Matthew Klebanoff and colleagues at the University of Pennsylvania documented a shift that would have been hard to predict even two years ago: prior authorization requirements for GLP-1 receptor agonists went from covering 2.8% to 5.0% of beneficiaries through 2023 to 99.9% to 100% by 2025.

To put that in context: in 2022, roughly 97 out of 100 Medicare beneficiaries could get a GLP-1 prescribed without prior authorization. By 2025, essentially none could.

The same study found that out-of-pocket costs climbed alongside. Monthly costs for established GLP-1s rose from $75-$138 in 2024 to $122-$167 in 2025. For beneficiaries in standalone Part D plans specifically, costs ranged from $99-$109 in 2024 and jumped to $175-$196 in 2025. Medicare Advantage Part D plans showed a more moderate increase, from $52-$64 to $93-$101 over the same period.

What drove both changes? The 2022 Inflation Reduction Act. The IRA introduced a $2,000 annual out-of-pocket cap for Part D beneficiaries (rising to $2,100 in 2026), which directly benefits patients. But the IRA paid for that cap partly by increasing Part D plans' financial liability from 15% to 60% of spending in the catastrophic coverage phase. Plans responded predictably: they tightened the gate. Prior authorization became the tool of choice to control which patients could access expensive GLP-1s.

The coinsurance numbers tell the same story. Plans requiring coinsurance (a percentage of the drug cost) rather than flat copays jumped from 27%-36% of beneficiaries in 2024 to 49%-77% in 2025. Coinsurance exposes patients to more of the drug's actual cost, discouraging use of expensive medications.

"Coverage is more nuanced than a yes-no decision," Dr. Klebanoff explained in a Penn LDI analysis. Even when a plan technically covers a GLP-1, the layers of prior authorization, step therapy, and coinsurance can make access functionally impossible for many patients. His warning applies to the Bridge program too: lower negotiated prices could actually lead plans to make prior authorization for Part D-covered GLP-1 indications (like diabetes) more burdensome, since wider GLP-1 use increases their total spending exposure.

The Bridge program's own prior authorization process, managed by Humana's central processor, has not yet been fully detailed. CMS promised additional operational guidance in Spring 2026. What we know: providers submit PA requests to the central processor rather than to the patient's Part D plan, and they attest to the clinical criteria rather than submitting extensive medical records. Whether that translates to a smoother experience than the typical Part D prior auth remains to be seen.

The Medicaid retreat: states pulling back GLP-1 coverage while Medicare expands it

While Medicare is building a bridge toward GLP-1 coverage, Medicaid is moving in the opposite direction. The number of states covering GLP-1s for obesity under Medicaid dropped from 16 in October 2025 to 13 by January 2026, and the trend may not be finished.

Four states — California, New Hampshire, Pennsylvania, and South Carolina — simultaneously stopped covering adult GLP-1 prescriptions for obesity on January 1, 2026. Three more — Michigan, Rhode Island, and Wisconsin — are planning or considering similar restrictions, according to KFF's survey. North Carolina pulled back coverage in October 2025, then reinstated it in December under court order, illustrating how contentious these decisions have become.

State	Status (as of early 2026)	Details
California	Cut Jan 1, 2026	Projected costs would have quadrupled to ~$800M/year; under-21 still covered
Pennsylvania	Cut Jan 1, 2026	Adults 21+ no longer covered for weight loss; other indications remain
New Hampshire	Cut Jan 1, 2026	Adult obesity coverage ended
South Carolina	Cut Jan 1, 2026	Adult obesity coverage ended
North Carolina	Reinstated Dec 2025	Pulled back in October, reinstated by court order
Michigan	Considering cuts	Planning or considering restrictions
Rhode Island	Considering cuts	Planning or considering restrictions
Wisconsin	Considering cuts	Planning or considering restrictions

The budget math explains these decisions. California projected that its GLP-1 weight loss costs would have more than quadrupled over four years to nearly $800 million annually if it maintained Medi-Cal coverage. By 2024, the state had covered more than 645,000 GLP-1 prescriptions across all indications. Cutting weight loss coverage was written directly into the state's budget law, and the Department of Finance has said it has no plans to reconsider, even after the TrumpRx price reductions were announced.

In Pennsylvania, the Department of Human Services ended adult GLP-1 coverage for weight loss effective January 1, 2026. Adults can still receive GLP-1s for type 2 diabetes, obstructive sleep apnea in people with obesity, cardiovascular risk reduction, and MASH (metabolic-associated steatohepatitis). Children and young adults under 21 remain covered for weight loss under the federal EPSDT (Early and Periodic Screening, Diagnosis and Treatment) requirement.

"It will be quite negative for our patients," said Dr. Diana Thiara, medical director of the UC San Francisco Weight Management Program, because research consistently shows people regain weight after stopping GLP-1 medications. Dr. Kurt Hong, founding director of the Center for Clinical Nutrition at USC Keck School of Medicine, added that diet and exercise recommendations alone are "frequently not enough" by the time patients reach their doctors, since most have already tried and failed those approaches.

The BALANCE Model may eventually reverse some of these cuts. State Medicaid agencies can opt into BALANCE on a rolling basis from May 2026 through January 2027, gaining access to lower negotiated GLP-1 prices through supplemental rebate agreements. But participation is voluntary, and states facing budget pressures from federal Medicaid funding cuts may hesitate. KFF has observed that interest in covering GLP-1s for obesity "appears to be waning" among state Medicaid programs.

From December 2025 to December 2031: every date that matters

The GLP-1 coverage expansion involves overlapping programs with different start dates, application windows, and decision points. Missing a deadline could mean missing months of coverage. Here is the full sequence:

Date	Event
December 23, 2025	CMS announces the BALANCE Model and the Medicare GLP-1 Bridge
January 8, 2026	Deadline for manufacturers to notify CMS of interest in BALANCE participation
Spring 2026	CMS releases additional Bridge operational guidance (prior auth processes, pharmacy details)
April 20, 2026	Deadline for Part D plan sponsors to apply for BALANCE Model participation
April 30, 2026	CMS notifies Part D sponsors whether 80% participation threshold is met
May 1, 2026	BALANCE Model launches in Medicaid for early-participating states
June 1, 2026	Part D plan sponsors confirm whether they will participate in BALANCE
July 1, 2026	Medicare GLP-1 Bridge goes live nationwide
July 31, 2026	State Medicaid agency Request for Applications deadline for BALANCE
October 15 - December 7, 2026	Medicare Open Enrollment: choose a 2027 Part D plan that participates in BALANCE
December 31, 2026	Medicare GLP-1 Bridge ends
January 1, 2027	BALANCE Model launches in Medicare Part D; Medicare Drug Price Negotiation price for semaglutide takes effect
December 2031	BALANCE Model ends for both Medicaid and Medicare Part D

The 80% participation threshold is the critical unknown. CMS has said that if fewer than 80% of Part D plan enrollment is represented by sponsors who apply to participate in BALANCE, the model will not move forward in Medicare for 2027. That notification deadline — April 30, 2026 — is only weeks away. If BALANCE doesn't launch, beneficiaries who started GLP-1s during the Bridge period could lose access entirely on January 1, 2027.

Even if BALANCE does launch, maintaining coverage requires action during Open Enrollment (October 15 through December 7, 2026). You will need to enroll in a Part D plan that has opted into BALANCE. Not all plans will participate. If your current plan doesn't join, you must switch — which could affect coverage and costs for your other medications.

For the safety profile and side effect management of these medications during a potential transition between coverage programs, having a clear medication history documented with your provider will be important.

Denied? The five-level appeal system and how to use it

If your prior authorization request under the Bridge program is denied, or if your Part D plan denies coverage of a GLP-1 for a covered indication like diabetes, you have appeal rights. Medicare's appeal system has five levels, and the process favors people who understand each step.

Level 1 — Redetermination from your plan. You, your representative, or your prescriber file within 65 days of the denial notice. Include your name, Medicare number, the drug being appealed, the reason for the appeal, and any supporting medical documentation. Your plan must respond within 7 days for a standard benefits appeal, or 72 hours if you request an expedited review by demonstrating that waiting could seriously harm your health.

Level 2 — Independent Review Entity (IRE). If your plan upholds the denial, you have 60 days to file a reconsideration with a Part D IRE. This is an independent review — the IRE is not affiliated with your plan. Same response deadlines: 7 days standard, 72 hours expedited.

Level 3 — Office of Medicare Hearings and Appeals (OMHA). If the IRE upholds the denial, you have 60 days to request a hearing before an administrative law judge. The amount in controversy must meet a minimum threshold ($190 in 2025, adjusted annually).

Level 4 — Medicare Appeals Council. You have 60 days from the Level 3 decision to request review.

Level 5 — Federal district court. Available if the amount in controversy meets a higher threshold ($1,910 in 2025).

Practical advice: most GLP-1 denials that get overturned are resolved at Levels 1 or 2. The single most effective action is having your prescriber write a detailed supporting statement explaining why the medication is medically necessary for your specific clinical situation, including failed prior treatments.

For Medicaid beneficiaries in states that have cut GLP-1 coverage for weight loss, the appeal process works differently, but options exist. In Pennsylvania, the Health Law Project advises filing an appeal within 15 days of receiving the coverage termination letter to maintain medication coverage during the appeal process. If you appeal after that 15-day window but before December 31, coverage continuation during the appeal is not guaranteed.

For adults whose GLP-1 is prescribed for an indication other than weight loss — type 2 diabetes, cardiovascular risk reduction, sleep apnea, or MASH — you should have your doctor submit a new prior authorization request specifying the covered indication. The coverage cuts target weight loss specifically; other indications remain covered in these states.

Beyond the formal process, these strategies improve your odds:

• Request an expedited review whenever possible. If your doctor can attest that a gap in GLP-1 therapy could cause medical harm (weight regain leading to worsened cardiovascular markers, for example), the 72-hour timeline is available.
• Ask your plan for a formulary exception if the specific GLP-1 you need is not on their formulary. Your prescriber must provide a statement explaining why the formulary alternatives are not appropriate for your clinical situation.
• Document everything. Keep copies of all correspondence, note dates and names of anyone you speak with, and send appeal materials by certified mail or equivalent tracked method.
• Contact 1-800-MEDICARE (1-800-633-4227) if you need help understanding your appeal rights or if your plan is not processing your appeal within the required timelines.

Frequently Asked Questions

Can I use the GLP-1 Bridge if I'm already taking Ozempic for diabetes through my Part D plan?

No. The Bridge covers GLP-1s only when prescribed for weight loss/obesity. If you're taking a GLP-1 for a Medicare-covered indication like type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea, you continue accessing it through your Part D plan. The Bridge is specifically for the obesity indication that Medicare has historically been prohibited from covering.

Will my $50 Bridge copay count toward my Part D out-of-pocket maximum?

No. Because the Bridge operates outside the Part D benefit structure, the $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap. This also means Low-Income Subsidy (Extra Help) cost-sharing subsidies do not apply to the Bridge copay.

What happens to my coverage when the Bridge ends on December 31, 2026?

To maintain GLP-1 coverage for obesity, you must enroll in a Part D plan that participates in the BALANCE Model for 2027 during Open Enrollment (October 15 - December 7, 2026). If your current plan doesn't participate, you'll need to switch plans. If the BALANCE Model doesn't meet the 80% participation threshold, Medicare GLP-1 obesity coverage could end entirely after the Bridge.

I lost weight on my GLP-1 and my BMI is now below the qualifying threshold. Can I still qualify?

Yes. CMS evaluates BMI at the time you first started GLP-1 therapy, not at the time of the prior authorization request. Your provider attests to your BMI when treatment was initiated, even if that was before the Bridge program launched.

Does the Bridge program cover Mounjaro or Ozempic?

Not directly. The Bridge covers Wegovy and Zepbound specifically because these are the formulations approved for weight loss. Mounjaro (tirzepatide for diabetes) and Ozempic (semaglutide for diabetes) are approved for other indications and remain available through regular Part D coverage. The broader BALANCE Model starting in 2027 will include all formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy, plus the Zepbound KwikPen.